GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Accumulated other comprehensive income (loss)

OGN (Organon) Accumulated other comprehensive income (loss) : $-617 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Organon Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Organon's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was $-617 Mil.

Organon's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2024 ($-571 Mil) to Dec. 2024 ($-649 Mil) but then increased from Dec. 2024 ($-649 Mil) to Mar. 2025 ($-617 Mil).

Organon's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 ($-564 Mil) to Dec. 2023 ($-541 Mil) but then declined from Dec. 2023 ($-541 Mil) to Dec. 2024 ($-649 Mil).


Organon Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Organon's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Accumulated other comprehensive income (loss) Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial -622.00 -513.00 -564.00 -541.00 -649.00

Organon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -577.00 -612.00 -571.00 -649.00 -617.00

Organon Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


Organon Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Organon's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Organon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Accumulated other comprehensive income (loss)
Traded in Other Exchanges
Address
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Executives
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione officer: Chief Human Resources Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kirke Weaver officer: Gen. Counsel & Corp. Secy. 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Kevin Ali officer: Chief Executive Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Matthew M Walsh officer: Chief Financial Officer ALLERGAN, 5 GIRALDA FARMS, MADISON NJ 07940
Ma. Fatima Francisco director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Sandra Milligan officer: Head of Research & Development 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Kathryn Dimarco officer: Corporate Controller 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler officer: Chief Commercial Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita officer: Head of Global Business Svcs 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr. officer: Head of Manufacturing 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Helene D Gayle director C/O COLGATE PALMOLIVE COMPANY, 300 PARK AVENUE, NEW YORK NY 10022
Deborah R Leone director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033

Organon Headlines

From GuruFocus